Does Opdivo plus Yervoy help patients live longer than chemotherapy (Checkmate 227)?
Applies to First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)
Note: Results are from Checkmate 227 Part 1a: first-line treatment in patients with PD-L1 ≥1%.
What was progression-free survival with Opdivo plus Yervoy in Checkmate 227?
Applies to First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)
Note: Results are from Checkmate 227 Part 1a: first-line treatment in patients with PD-L1 ≥1%.
What response rate did Opdivo plus Yervoy achieve in Checkmate 227?
Applies to First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)
Note: Results are from Checkmate 227 Part 1a: first-line treatment in patients with PD-L1 ≥1%.
Does Opdivo plus Yervoy and chemo improve survival (Checkmate 9LA)?
Applies to First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)
Does Opdivo plus Yervoy and chemotherapy delay progression (Checkmate 9LA)?
Applies to First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)
What response rate did Opdivo plus Yervoy and chemotherapy achieve (Checkmate 9LA)?
Applies to First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)
Note: The first result is from Checkmate 057 (non-squamous) and the second from Checkmate 017 (squamous), as labeled on the efficacy page.
Clinical trials
How was the Opdivo plus Yervoy Checkmate 227 trial designed?
Applies to First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)
How was the Checkmate 9LA trial of Opdivo, Yervoy, and chemotherapy designed?
Applies to First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)
Note: Checkmate 67T enrolled adults with previously treated advanced or metastatic clear cell renal cell carcinoma.
Subgroup results
Opdivo plus Yervoy and chemo at PD-L1 below 1%: Checkmate 9LA results?
Applies to First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)